NCT06127238View on ClinicalTrials.gov

Study of ST-1898 in Advanced Renal Cell Carcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG

ST-1898 tablets

Supplied as 5 mg and 40 mg tablets

Trial Locations (1)

100142

Peking University Cancer Hospital & Institute, Beijing

Sponsors
All Listed Sponsors
lead

Beijing Scitech-Mq Pharmaceuticals Limited

INDUSTRY